AbbVie says EU approves Rinvoq for non-segmental vitiligo treatment
ABBV•EU approves Rinvoq for vitiligo
AbbVie says the European Commission has granted clearance for Rinvoq (upadacitinib) 15 mg once daily for non-segmental vitiligo in patients aged 12 and older.
- Rinvoq becomes the EU’s first systemic treatment for the condition, expanding AbbVie’s dermatology franchise into a new indication.
- The approval was backed by Phase 3 Viti-Up data showing significant facial and total-body repigmentation at week 48 versus placebo.
- The drug remains under U.S. FDA review for non-segmental vitiligo.
